Novel Approaches to the Management of Advanced Peripheral Artery Disease: Perspectives on Drug-Coated Balloons, Drug-Eluting Stents, and Bioresorbable Scaffolds

Current Cardiology Reports

Volumn 17, Issue 9, 2015, Pages

  Zeller, Thomas ^a   Rastan, Aljoscha ^a   Macharzina, Roland ^a   Beschorner, Ulrich ^a   Noory, Elias ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

Angioplasty; Bioresorbable stent; Drug coated balloon; Drug eluting balloon; Drug eluting stent; Paclitaxel; Peripheral artery disease; Superficial femoral artery

Indexed keywords

BALLOON; BARE METAL STENT; BIOMIMETIC STENT; BIORESORBABLE SCAFFOLD; CLINICAL EFFECTIVENESS; COST CONTROL; DEVICE APPROVAL; DISEASE CLASSIFICATION; DISEASE REGISTRY; DISEASE SEVERITY; DRUG COATED BALLOON; DRUG ELUTING STENT; EQUIPMENT DESIGN; HUMAN; INTERMETHOD COMPARISON; MEDICAL TECHNOLOGY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STENT; THERAPY EFFECT; VASCULAR PATENCY; BIODEGRADABLE IMPLANT; BLOOD FLOW VELOCITY; FEMORAL ARTERY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROCEDURES; TRENDS;

BIOMATERIAL; CARDIOVASCULAR AGENT;

ABSORBABLE IMPLANTS; ANGIOPLASTY, BALLOON; BLOOD FLOW VELOCITY; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; DRUG-ELUTING STENTS; FEMORAL ARTERY; HUMANS; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; VASCULAR PATENCY;

EID: 84938601149     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-015-0624-6     Document Type: Review

References (37)

1. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease. Int Angiol. 2007;26:81–157.
2. Beschorner U, Sixt S, Schwarzwälder U, et al. Recanalization of chronic occlusions of the superficial femoral artery using the outback™ re-entry catheter: a single centre experience. Cath Cardiovasc Interv. 2009;74:934–8.
3. Johnston KW. Femoral and popliteal arteries: reanalysis of results of balloon angioplasty. Radiology. 1992;183:767–71.
4. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–88.
5. Krankenberg H, Schlüter M, Steinkamp HJ, et al. Nitinol stent implantation vs. percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116:285–92.
6. Laird JR, Katzen BT, Scheinert D, et al. Resilient investigators. nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3(3):267–76.
7. Scheinert D, Scheinert S, Sax J, Piorkowski C, Bräunlich S, Ulrich M, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45(2):312–5.
8. Klinkert P, Schepers A, Burger DH, van Bockel JH, Breslau PJ. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized controlled trial. J Vasc Surg. 2003;37:149–55.
9. Pereira CE, Albers M, Romiti M, Brochado-Neto FC, Pereira CA. Meta-analysis of femoropopliteal bypass grafts for lower extremity arterial insufficiency. J Vasc Surg. 2006;44:510–7.
10. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–99.
11. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–65.
12. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: 12-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504.
13. Dake M, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: two-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61(24):2417–27. This study describes in detail the 2-year outcome and benefit of DES over standard of care therapy in femoro-popliteal lesions.
14. Dake M, Bosiers M, Fanelli F, Kavteladze Z, Lottes A, Ragheb A, et al. A single-arm clinical study of the safety and effectiveness of the zilver® ptx® drug-eluting peripheral stent: twelve-month results. JEVT. 2011;18:613–23.
15. Lammer J, Zeller T, Hausegger K, Schaefer P, Gschwendtner M, Mueller-Huelsbeck S, et al. Heparin-bonded covered stents versus bare metal stents for symptomatic peripheral arterial disease: the VIASTAR trial. J Am Coll Cardiol. 2013;62:1320–7.
16. Lammer J, Zeller T, Hausegger KA, Schaefer PJ, Gschwendtner M, Mueller-Huelsbeck S, et al. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovasc Intervent Radiol 2014; DOI 10.1007/s00270-014-1024-9
17. Zeller T, Peeters P, Bosiers M, Lammer J, Brechtel K, Scheinert D, et al. Heparin bonded stent-graft for the treatment of TACS II C and D femoro-popliteal artery lesions: The Viabahn-25 cm trial. JEndovasc Ther. 2014;21:765–74.
18. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and/or popliteal peripheral artery disease: 12-month results from the in.pact sfa randomized trial. Circulation. 2015;131:495–502. This large scale pivotal study resulted in the best DCB mid-term outomes in the treatment of TASC II A and B SFA lesions published so far.
19. Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Müller-Hülsbeck S, Nehler MR, Benenati JF, Scheinert D. Randomized trial of paclitaxel-coated balloon for femoropopliteal artery disease. NEJM 2015, in press. This is the largest study confirming the mid-term benefit of DCB compared to plain balloon angioplasty in the treatment of short femoro-popliteal lesions.
20. Lammer J, Bosiers M, Deloose K, Schmidt A, Zeller T, Lansink W, Sauguet A, Vermassen F, Lauwers G, Wolf F, Scheinert D, Jaff MR, Popma JJ, McGreevy R, Rapoza R. Bioresorbable everolimus-eluting vascular scaffold for patients with peripheral artery disease (ESPRIT I): two-year clinical and imaging results. JACC in revision.
21. Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, et al. The LEVANT I trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. J Am Cardiol Cardiol Intv. 2014;7:10–9.
22. Werk M, Albrecht T, Meyer D-R, Ahmed MN, Behne A, Dietz U, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831–40.
23. Scheinert D, Schulte KL, Zeller T, Lammer J, Tepe G. Novel paclitaxel releasing balloon in femoropopliteal lesions: 12-month evidence from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22:14–21.
24. Micari A, Cioppa A, Vadalà G, Castriota F, Liso A, Marchese A, et al. Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry. J Am Cardiol Cardiol Intv. 2012;5:331–8.
25. Schroeder H, Meyer DR, Lux B, Ruecker F, Martorana M, Duda S. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study. Catheter Cardiovasc Interv. 2015 Feb 23. doi: 10.1002/ccd.25900
26. Cassese S, Byrne RA, Ott I, Ndrepepa G, Nerad M, Kastrati A, et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2012;5:582–9.
27. Tepe G, Zeller T, Schnorr B, Claussen CD, Beschorner U, Brechtel K, et al. High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study. J Endovasc Ther. 2013;20:792–800.
28. Tepe G, Schnorr B, Albrecht T, Brechtel K, Claussen CD, Scheller B, et al. Five-year follow-up data of the Thunder trial: angioplasty of femoro-popliteal arteries with drug-coated balloons. J Am Cardiol Cardiol Intv. 2015;1:102–8. This study reports the sustained long-term clinical benefit of DCB treatment of femoro-popliteal artery disease.
29. Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, et al. Drug eluting balloons vs. drug eluting stents in long femoropopliteal lesions—a retrospective propensity score analysis. J Endovasc Ther. 2014;21:359–68.
30. Dick P, Sabeti S, Mlekusch W, Schlager O, Amighi J, Haumer M, et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology. 2008;248:297–302.
31. Stabile E, Virga V, Salemme L, Cioppa A, Ambrosini V, Sorropago G, et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol. 2012;60:1739–42.
32. Virga V, Stabile E, Biamino G, Salemme L, Cioppa A, Giugliano G, et al. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. J Am Cardiol Cardiol Intv. 2014;7:411–5.
33. Bosiers M, Peeters P, Tessarek J, Deloose K, Strickler S, Antoniucci D, et al. The Zilver® PTX® single arm study: 12-month results from the TASC C/D lesion subgroup. J Cardiovasc Surg (Torino). 2013;54(1):115–22.
34. Zeller T, Dake MD, Tepe G, Brechtel K, Noory E, Beschorner U, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. J Am Cardiol Cardiol Intv. 2013;6:274–81.
35. Bosiers M, Peeters P, D’Archambeau O, Hendriks J, Pilger E, Düber C, et al. AMS INSIGHT-absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Intervent Radiol. 2009;32:424–35.
36. Caro CG. Discovery of the role of wall shear in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:158–61.
37. Pietzsch JB, Geisler BP, Garner AM, Zeller T, Jaff MR. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany. Catheter Cardiovasc Interv. 2014;84:546–54.